The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome.

Thromb Res

Departamento de Educación, Instituto de Efectividad Clínica y Sanitaria (IECS), Dr. Emilio Ravignani 2024, Ciudad de Buenos Aires, Argentina.

Published: October 2021

Background: The use of low-dose aspirin (LDA) and heparin has improved pregnancy outcomes in women with antiphospholipid syndrome (APS). However, 20-30% still have adverse outcomes despite treatment. Recent retrospective studies showed a beneficial effect of hydroxychloroquine (HCQ) in APS due to its anti-inflammatory, immunomodulatory and antithrombotic properties. Data in refractory obstetric APS (OAPS) remain scarce and include heterogeneous populations with various concomitant treatments.

Objective: The objective of this study was to assess the impact on the obstetric outcomes of adding HCQ to classical treatments for women with refractory primary obstetric APS.

Methods: In a retrospective single-centre cohort study, we compared pregnancy outcomes in women with refractory primary OAPS (2004-2019) who received two different treatments in subsequent pregnancies. Group A received 400 mg HCQ + 60 mg enoxaparin + LDA, while Group B received 60 mg enoxaparin + LDA. The main outcome was live birth rates, while pregnancy complications (early and late pregnancy losses and placental-mediated complications) were the secondary outcome.

Results: A total of 101 pregnancies in 87 refractory primary OAPS patients were included. The rate of live-born babies in Group A (HCQ) was 97.1% (67/69) vs. 62.5% (20/32) in Group B (RR: 1.55 [95% CI, 1.19-2.1]; p < 0.001). Pregnancy complications in Group A were 8.7% (6/69) vs. 37.5% (12/32) in Group B (RR 0.22 [95% CI, 0.15-0.30]; p < 0.001).

Conclusion: Hydroxychloroquine was associated with a higher rate of live births and a lower prevalence of pregnancy complications in refractory primary obstetric APS. The addition of HCQ to classical treatment may present a promising approach that needs to be confirmed with prospective studies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2021.08.004DOI Listing

Publication Analysis

Top Keywords

refractory primary
12
obstetric outcomes
8
refractory obstetric
8
antiphospholipid syndrome
8
pregnancy outcomes
8
outcomes women
8
women refractory
8
primary oaps
8
group received
8
enoxaparin lda
8

Similar Publications

Intracameral voriconazole for severe fungal keratitis: a case series.

Arq Bras Oftalmol

January 2025

Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.

Purpose: This study aimed to report the use, efficacy, and safety of intracameral voriconazole as an adjuvant treatment for deep fungal keratitis.

Methods: This was a prospective case series of seven eyes with fungal keratitis with anterior chamber involvement or a corneal ulcer refractory to conventional topical treatment. In addition to topical treatment with 0.

View Article and Find Full Text PDF
Article Synopsis
  • Anlotinib has demonstrated positive effects in treating platinum-resistant ovarian cancer, but its role as a maintenance therapy after initial treatment was unclear.
  • In a phase II clinical trial with 24 patients, those who received anlotinib after responding to chemotherapy had a median progression-free survival of 15.8 months and an overall survival of 43.8 months.
  • The study indicated that anlotinib is a safe and effective option for maintenance therapy, showing promise in extending survival for patients with advanced ovarian cancer.
View Article and Find Full Text PDF

Background Endoscopic dilatation is the cornerstone therapy for esophageal strictures. The primary indication for dilatation is to provide immediate and durable symptomatic relief from dysphagia. Following esophageal dilatation, the two most common major consequences are bleeding and perforation, both of which are quite rare.

View Article and Find Full Text PDF

Background: Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), often results in significant morbidity among patients with moderate to severe forms. While biologics and small molecules are effective in inducing remission, many patients experience refractory disease or extraintestinal manifestations. This study assesses the safety and efficacy of dual-targeted therapy in IBD patients treated at the Inflammatory Bowel Disease Center.

View Article and Find Full Text PDF

Lipohypertrophy is the most reported cutaneous complication of insulin injection. In cases refractory to conservative management, liposuction has been proposed as a treatment. This review aims to evaluate the use of liposuction for the treatment of insulin-induced lipohypertrophy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!